NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

神經痛治療的全球市場 - 市場規模·市場佔有率·趨勢分析報告:治療·最終用途·地區·各市場區隔的預測 (2020∼2027年)

Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment (Drug Based, Surgeries ); By End-Use; By Region, and Segment Forecasts, 2020 - 2027

出版商 Polaris Market Research 商品編碼 986404
出版日期 內容資訊 英文 112 Pages
商品交期: 最快1-2個工作天內
價格
神經痛治療的全球市場 - 市場規模·市場佔有率·趨勢分析報告:治療·最終用途·地區·各市場區隔的預測 (2020∼2027年) Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment (Drug Based, Surgeries ); By End-Use; By Region, and Segment Forecasts, 2020 - 2027
出版日期: 2020年12月01日內容資訊: 英文 112 Pages
簡介

全球神經痛治療的市場規模在2027年前將達到28億3000萬美元。

本報告提供全球神經痛治療市場相關調查,提供市場概要與趨勢,各市場區隔·各地區的趨勢分析與市場佔有率,競爭情形,並提供主要企業簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
    • 調查目的
    • 市場範圍
    • 前提條件
  • 相關利益者

第2章 摘要整理

  • 市場亮點

第3章 調查手法

  • 概要
    • 資料探勘
  • 資料來源
    • 主要資源
    • 次要來源

第4章 神經痛治療市場考察

  • 神經痛治療:產業的概述
  • 神經痛治療市場動態
    • 推動要素和機會
    • 阻礙因素與課題
  • 波特的五力分析
    • 供給企業談判力(中)
    • 新加入廠商者的威脅:(低)
    • 買方議價能力(中)
    • 替代威脅(中)
    • 現有企業間的競爭(量)
  • 大環境分析
  • 產業趨勢

第5章 神經痛治療的市場評估:各治療法

  • 主要調查結果
  • 簡介
    • 全球神經痛治療市場:各治療法 (以金額為準)
  • 藥物型
    • 全球神經痛治療市場:藥物型 - 各地區 (以金額為準)
    • 抗痙攣藥
    • 三環抗憂鬱藥物
  • 手術
    • 全球神經痛治療市場:手術 - 各地區 (以金額為準)
    • 球囊壓縮
    • 丙三醇注射
    • 高頻熱病變
    • 立體定位放射線治療
    • 微小血管減壓手術

第6章 神經痛治療的市場評估:最終用途

  • 主要調查結果
  • 簡介
    • 全球神經痛治療市場:最終用途 (以金額為準)
  • 醫院&診所
    • 全球神經痛治療市場:醫院&診所 - 各地區 (以金額為準)
  • 外科門診診療所 (ASC)
    • 全球神經痛治療市場:外科門診診療所 - 各地區 (以金額為準)
  • 其他
    • 全球神經痛治療市場:其他 - 各地區 (以金額為準)

第7章 神經痛治療的市場評估:各地區

  • 主要調查結果
  • 簡介
    • 神經痛治療市場評估:各地區 (以金額為準)
  • 北美市場
    • 各治療法 (以金額為準)
    • 最終用途 (以金額為準)
    • 美國
    • 加拿大
  • 歐洲市場
    • 各治療法 (以金額為準)
    • 最終用途 (以金額為準)
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 奧地利
  • 亞太地區市場
    • 各治療法 (以金額為準)
    • 最終用途 (以金額為準)
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
  • 中東·非洲市場
    • 各治療法 (以金額為準)
    • 最終用途 (以金額為準)
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
  • 南美市場
    • 各治療法 (以金額為準)
    • 最終用途 (以金額為準)
    • 墨西哥
    • 巴西
    • 阿根廷

第8章 競爭情形

  • 擴張與收購分析
    • 擴張
    • 收購
  • 夥伴關係/合作/契約/展示會

第9章 企業簡介

  • Allergan Plc
  • Merz Pharma GmbH & Co.
  • Abbott Laboratories
  • Trigemina Inc.
  • Pfizer Inc.
  • Novartis
  • GlaxoSmithKline Plc.
  • Lupin
  • Cadila Healthcare Limited
  • Lundbeck Pharmaceuticals LLC
  • Biogen
目錄
Product Code: PM1763

Title:
Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment (Drug Based [Anticonvulsant Medicines, Tricyclic Antidepressants], Surgeries [Balloon Compression, Glycerol Injection, Radiofrequency Thermal Lesioning, Stereotactic Radiosurgery, Microvascular Decompression]); By End-Use; By Region, and Segment Forecasts, 2020 - 2027.

The global neuralgia treatment market size is predicted to reach USD 2.83 billion by 2027 according to a new study by Polaris Market Research. The report "Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment (Drug Based [Anticonvulsant Medicines, Tricyclic Antidepressants], Surgeries [Balloon Compression, Glycerol Injection, Radiofrequency Thermal Lesioning, Stereotactic Radiosurgery, Microvascular Decompression]); By End-Use; By Region, And Segment Forecasts, 2020 - 2027" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The neuralgia treatment market is expected to witness significant growth owing to the increasing incidences of diabetes and trigeminal neuralgia. Furthermore, multiple sclerosis is also one of factors which can cause neuralgia. Multiple sclerosis decreases the body immunity owing to the neurodegenerative condition which affects the myelin sheath that can cause neuralgia. This is likely to drive market demand over the forecast period.

The potential drug candidates and the expected drug approval is expected to stimulate the global market, with high concentration of pharmaceutical companies engaged in the research & development of novel drugs for neuralgia treatment. For instance, U.S-based drug manufacturer, Biogen Inc. is developing BIIB074 (Vixotrigine) for the treatment of trigeminal neuralgia and is currently in phase II.

Market participants such as Allergan Plc, GlaxoSmithKline Plc., Biogen, Inc., Abbott Laboratories, PixarBio Corporation, Merz Pharma GmbH, Trigemina Inc., Pfizer Inc., Novartis, Lupin, and others. are some of the key players operating in the global market. Biohaven pharmaceuticals has Rimegepant in the phase II clinical trials and it is estimated to be completed by December 2020. The drug is a potent antagonist of the CGRP receptor. The receptor is responsible for neural sensitization and neuropathic pain.

In May 2020, CODA Biotherapeutics, Inc. (CODA), the U.S.-based clinical stage pharmaceutical company currently in the process of developing gene therapy based chemogenetic platform announced the collaboration with the Facial Pain Research Foundation (FPRF) to utilize company's proprietary platform to develop potential therapies and treatment options for the trigeminal neuralgia and other neurological conditions.

Polaris Market Research has segmented the neuralgia treatment market report on the basis of treatment, indication, distribution channel, and region

Neuralgia Treatment, By Treatment (Revenue - USD Million, 2016 - 2027)

Drug Based

Anticonvulsant Medicines

Carbamazepine

Oxcarbazepine

Topiramate

Gabapentin

Pregabalin

Clonazepam

Phenytoin

Lamotrigine

Valproic Acid

Tricyclic Antidepressants

Amitriptyline

Nortriptyline

Surgeries

Balloon Compression

Glycerol Injection

Radiofrequency Thermal Lesioning

Stereotactic Radiosurgery

Microvascular Decompression

Neuralgia Treatment, By End-Use (Revenue - USD Million, 2016 - 2027)

Hospitals & Clinics

Ambulatory Surgery Centers

Others

Neuralgia Treatment, By Regional Outlook (Revenue - USD Million, 2016 - 2027)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Austria

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Central & South America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Neuralgia Treatment Market Insights

  • 4.1. Neuralgia Treatment - Industry snapshot
  • 4.2. Neuralgia Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High incidence rate of Neuralgia
      • 4.2.1.2. Sports injuries causing neuro-degenrative disorders
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Neuralgia Treatment Market Industry trends

5. Neuralgia Treatment Market Assessment by Treatment

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • 5.3. Drug Based
    • 5.3.1. Global Neuralgia Treatment Market, by Drug Based, by Region, 2016 - 2027 (USD Million)
    • 5.3.2. Anticonvulsant Medicines
      • 5.3.2.1. Anticonvulsant Medicines Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.2. Carbamazepine
      • 5.3.2.2.1. Carbamazepine Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.3. Oxcarbazepine
      • 5.3.2.3.1. Oxcarbazepine Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.4. Topiramate
      • 5.3.2.4.1. Topiramate Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.5. Gabapentin
      • 5.3.2.5.1. Gabapentin Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.6. Pregabalin
      • 5.3.2.6.1. Pregabalin Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.7. Clonazepam
      • 5.3.2.7.1. Clonazepam Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.8. Phenytoin
      • 5.3.2.8.1. Phenytoin Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.9. Lamotrigine
      • 5.3.2.9.1. Lamotrigine Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.2.10. Valproic Acid
      • 5.3.2.10.1. Valproic Acid Market, by Region, 2016 - 2027 (USD Million)
    • 5.3.3. Tricyclic Antidepressants
      • 5.3.3.1. Tricyclic Antidepressants Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.3.2. Amitriptyline
      • 5.3.3.2.1. Amitriptyline Market, by Region, 2016 - 2027 (USD Million)
      • 5.3.3.3. Nortriptyline
      • 5.3.3.3.1. Nortriptyline Market, by Region, 2016 - 2027 (USD Million)
  • 5.4. Surgery
    • 5.4.1. Global Neuralgia Treatment Market, by Surgery, by Region, 2016 - 2027 (USD Million)
    • 5.4.2. Balloon Compression
      • 5.4.2.1. Balloon Compression Market, by Region, 2016 - 2027 (USD Million)
    • 5.4.3. Glycerol Injection
      • 5.4.3.1. Glycerol Injection Market, by Region, 2016 - 2027 (USD Million)
    • 5.4.4. Radiofrequency Thermal Lesioning
      • 5.4.4.1. Radiofrequency Thermal Lesioning Market, by Region, 2016 - 2027 (USD Million)
    • 5.4.5. Stereotactic Radiosurgery
      • 5.4.5.1. Stereotactic Radiosurgery Market, by Region, 2016 - 2027 (USD Million)
    • 5.4.6. Microvascular Decompression
      • 5.4.6.1. Microvascular Decompression Market, by Region, 2016 - 2027 (USD Million)

6. Global Neuralgia Treatment Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • 6.3. Hospital & Clinics
    • 6.3.1. Global Neuralgia Treatment Market, by Hospital & Clinics, By Region, 2016 - 2027 (USD Million)
  • 6.4. Ambulatory Surgery Centers
    • 6.4.1. Global Neuralgia Treatment Market, by Ambulatory Surgery Centers, by Region, 2016 - 2027 (USD Million)
  • 6.5. Others
    • 6.5.1. Global Neuralgia Treatment Market, by Others, by Region, 2016 - 2027 (USD Million)

7. Neuralgia Treatment Market Assessment by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Neuralgia Treatment Market Assessment, By Geography, 2016 - 2027 (USD Million)
  • 7.3. Neuralgia Treatment Market - North America
    • 7.3.1. North America: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
    • 7.3.2. North America: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.3.3. Neuralgia Treatment Market - U.S.
      • 7.3.3.1. U.S.: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.3.3.2. U.S.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.3.4. Neuralgia Treatment Market - Canada
      • 7.3.4.1. Canada: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.3.4.2. Canada.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • 7.4. Neuralgia Treatment Market - Europe
    • 7.4.1. Europe: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
    • 7.4.2. Europe: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.3. Neuralgia Treatment Market - UK
      • 7.4.3.1. UK: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.3.2. UK: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.4. Neuralgia Treatment Market - France
      • 7.4.4.1. France: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.4.2. France: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.5. Neuralgia Treatment Market - Germany
      • 7.4.5.1. Germany: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.5.2. Germany: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.6. Neuralgia Treatment Market - Italy
      • 7.4.6.1. Italy: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.6.2. Italy: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.7. Neuralgia Treatment Market - Spain
      • 7.4.7.1. Spain: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.7.2. Spain: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.8. Neuralgia Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.8.2. Netherlands: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.4.9. Neuralgia Treatment Market - Austria
      • 7.4.9.1. Austria: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.4.9.2. Austria: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • 7.5. Neuralgia Treatment Market - Asia-Pacific
    • 7.5.1. Asia Pacific: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
    • 7.5.2. Asia Pacific: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.5.3. Neuralgia Treatment Market - China
      • 7.5.3.1. China: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.5.3.2. China: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.5.4. Neuralgia Treatment Market - India
      • 7.5.4.1. India: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.5.4.2. India.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.5.5. Neuralgia Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.5.5.2. Malaysia: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.5.6. Neuralgia Treatment Market - Japan
      • 7.5.6.1. Japan: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.5.6.2. Japan: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.5.7. Neuralgia Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.5.7.2. Indonesia: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.5.8. Neuralgia Treatment Market - South Korea
      • 7.5.8.1. South Korea: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.5.8.2. South Korea.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • 7.6. Neuralgia Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
    • 7.6.2. Middle East & Africa.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.6.3. Neuralgia Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.6.3.2. Saudi Arabia.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.6.4. Neuralgia Treatment Market - UAE
      • 7.6.4.1. UAE: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.6.4.2. UAE: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.6.5. Neuralgia Treatment Market - Israel
      • 7.6.5.1. Israel: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.6.5.2. Israel: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.6.6. Neuralgia Treatment Market - South Africa
      • 7.6.6.1. South Africa: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.6.6.2. South Africa: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • 7.7. Neuralgia Treatment Market - Latin America
    • 7.7.1. Latin America: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
    • 7.7.2. Latin America: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.7.3. Neuralgia Treatment Market - Mexico
      • 7.7.3.1. Mexico: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.7.3.2. Mexico.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.7.4. Neuralgia Treatment Market - Brazil
      • 7.7.4.1. Brazil: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.7.4.2. Brazil.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
    • 7.7.5. Neuralgia Treatment Market - Argentina
      • 7.7.5.1. Argentina: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
      • 7.7.5.2. Argentina.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Allergan Plc
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Merz Pharma GmbH & Co.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Abbott Laboratories
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Trigemina Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Pfizer Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Novartis
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. GlaxoSmithKline Plc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Lupin
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Cadila Healthcare Limited
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Lundbeck Pharmaceuticals LLC
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Biogen
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development

Truncated List of Tables

  • Table 1 Global Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 2 Global Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 3 Neuralgia Treatment Market Assessment, By Geography, 2016 - 2027 (USD Million)
  • Table 4 North America: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 5 North America: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 6 U.S.: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 7 U.S.: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 8 Canada: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 9 Canada: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 10 Europe: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 11 Europe: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 12 UK: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 13 UK: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 14 France: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 15 France: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 16 Germany: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 17 Germany: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 18 Italy: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 19 Italy: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 20 Spain: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 21 Spain: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 22 Netherlands: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 23 Netherlands: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 24 Austria: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 25 Austria: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 26 Asia Pacific: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 27 Asia Pacific: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 28 China: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 29 China: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 30 India: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 31 India: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 32 Malaysia: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 33 Malaysia: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 34 Japan: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 35 Japan: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 36 Indonesia: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 37 Indonesia: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 38 South Korea: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 39 South Korea: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 40 Middle East & Africa: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 41 Middle East & Africa: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 42 Saudi Arabia: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 43 Saudi Arabia: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 44 UAE: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 45 UAE: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 46 Israel: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 47 Israel: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 48 South Africa: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 49 South Africa: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 50 Latin America: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 51 Latin America: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 52 Mexico: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 53 Mexico: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 54 Brazil: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 55 Brazil: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)
  • Table 56 Argentina: Neuralgia Treatment Market, By Treatment, 2016 - 2027 (USD Million)
  • Table 57 Argentina: Neuralgia Treatment Market, By End Use, 2016 - 2027 (USD Million)

List of Figures

Figure 1 Market Highlights (2019, Revenue)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top Down & Bottom Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Treatment

Figure 7 Global Neuralgia Treatment Market, By Treatment, 2019 & 2027 (USD Million)

Figure 8 Market by End Use

Figure 9 Global Neuralgia Treatment Market, By End Use, 2019 & 2027 (USD Million)

Figure 10 Neuralgia Treatment Market Assessment, By Geography, 2016 - 2027 (USD Million)

Figure 11 Strategic Analysis - Neuralgia Treatment Market